BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17988433)

  • 1. Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice.
    Schreiber SA; Russmann A
    Curr Med Res Opin; 2007 Dec; 23(12):3131-6. PubMed ID: 17988433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
    Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
    Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
    Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
    Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Jan; 8():3. PubMed ID: 19152692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
    Siegmund T; Weber S; Blankenfeld H; Oeffner A; Schumm-Draeger PM
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):349-53. PubMed ID: 17701878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Honka M; Ackermann RW; Meriläinen M; Gallwitz B; Sreenan S;
    Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice.
    Schreiber SA; Russmann A
    Curr Med Res Opin; 2006 Feb; 22(2):335-41. PubMed ID: 16466605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
    Pan CY; Sinnassamy P; Chung KD; Kim KW;
    Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus.
    Chase HP; Arslanian S; White NH; Tamborlane WV
    J Pediatr; 2008 Oct; 153(4):547-53. PubMed ID: 18589448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E; Weatherley-Jones E; Chilcott J; Beverley C
    Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.